Caroline Chevalier - Zenas BioPharma, Chief Officer
| ZBIO Etf | USD 9.48 0.71 8.10% |
| Address | North Building, Waltham, MA, United States, 02451 |
| Phone | 857 271 2954 |
| Web | https://zenasbio.com |
Similar Fund Executives
| Found 12 records | One Year Return | ||
| David Beitel | Zillow Group Class | 54 | |
| Raj MD | enGene Holdings Common | N/A | |
| Dr MSc | enGene Holdings Common | 45 | |
| Jenny Arden | Zillow Group Class | N/A | |
| Bradley Berning | Zillow Group Class | N/A | |
| MBChB MFPM | enGene Holdings Common | 67 | |
| FACS MD | enGene Holdings Common | N/A | |
| Jun Choo | Zillow Group Class | N/A | |
| Joan Connolly | enGene Holdings Common | N/A | |
| Lee Giguere | enGene Holdings Common | 43 | |
| Jeremy Hofmann | Zillow Group Class | 37 | |
| Errol Samuelson | Zillow Group Class | 58 | |
Zenas BioPharma, Common Money Managers
| Jennifer Fox, Chief CFO | ||
| Orlando Oliveira, Chief Officer | ||
| Caroline Chevalier, Chief Officer | ||
| Joseph Farmer, COO President | ||
| Jeffrey Held, Chief Officer | ||
| MBA Moulder, CEO Board |
Zenas Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Zenas BioPharma, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| EBITDA | (56.31 M) | ||||
| Net Income | (37.12 M) | ||||
| Total Debt | 293.9 M | ||||
| Book Value Per Share | (21.07) X | ||||
| Cash Flow From Operations | (30.53 M) | ||||
| Earnings Per Share | (3.90) X | ||||
| Beta | -2.35 | ||||
| Market Capitalization | 673.29 M | ||||
| Total Asset | 68.18 M | ||||
| Retained Earnings | (230.4 M) |
Pair Trading with Zenas BioPharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zenas BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will appreciate offsetting losses from the drop in the long position's value.Moving together with Zenas Etf
| 0.76 | DWTX | Dogwood Therapeutics, Symbol Change | PairCorr |
Moving against Zenas Etf
| 0.88 | VAXX | Vaxxinity | PairCorr |
| 0.67 | EPRX | Eupraxia Pharmaceuticals | PairCorr |
| 0.6 | EVLO | Evelo Biosciences | PairCorr |
| 0.6 | GRCE | Grace Therapeutics, Symbol Change | PairCorr |
| 0.59 | CEROW | CERo Therapeutics Symbol Change | PairCorr |
The ability to find closely correlated positions to Zenas BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zenas BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zenas BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zenas BioPharma, Common to buy it.
The correlation of Zenas BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zenas BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zenas BioPharma, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zenas BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.